Answers are grounded in this paper and cite their sources.
In patients with type 2 diabetes at high cardiovascular risk, empagliflozin was associated with slower progression of kidney disease and lower rates of clinically relevant renal events than was placebo when added to standard care. (Funded by the Boehringer Ingelheim and Eli Lilly and Company Diabetes Alliance; EMPA-REG OUTCOME ClinicalTrials.gov number, NCT01131676.).
No takes yet. Share an insight, caveat, or question.
Wanner et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: